Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. (2021)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)01694-9
PubMed Identifier: 34370971
Publication URI: http://europepmc.org/abstract/MED/34370971
Type: Journal Article/Review
Volume: 398
Parent Publication: Lancet (London, England)
Issue: 10303
ISSN: 0140-6736